{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:13:00Z","timestamp":1788347580446,"version":"build-2803163510"},"reference-count":78,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2019,3,30]]},"DOI":"10.1536\/ihj.18-455","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T22:37:11Z","timestamp":1550788631000},"page":"241-246","source":"Crossref","is-referenced-by-count":20,"title":["Clinical Implications of Baroreflex Sensitivity in Type 2 Diabetes"],"prefix":"10.1536","volume":"60","author":[{"given":"Masaya","family":"Sakamoto","sequence":"first","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Matsutani","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kayama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Jikei University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Pop-Busui R, Evans GW, Gerstein HC, <i>et al<\/i>. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control cardiovascular Risk in Diabetes (Accord) trial. Diabetes Care 2010; 33: 1578-84.","DOI":"10.2337\/dc10-0125"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ewing DJ, Campbell IW, Clarke BF. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. Ann Intern Med 1980; 92: 308-11.","DOI":"10.7326\/0003-4819-92-2-308"},{"key":"3","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2337\/diacare.24.10.1793","volume":"24","year":"2001","unstructured":"3. Gerritsen J, Dekker JM, TenVoorde BJ, <i>et al<\/i>. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care 2001; 24: 1793-8.","journal-title":"Diabetes Care","ISSN":"https:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"4","unstructured":"4. La Rovere MT, Specchia G, Mortara A, Schwartz PJ. Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction. A prospective study. Circulation. A prospective study 1988; 78: 816-24."},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. La Rovere MT, Pinna GD, Hohnloser SH, <i>et al<\/i>. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 2001; 103: 2072-7.","DOI":"10.1161\/01.CIR.103.16.2072"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Spallone V, Ziegler D, Freeman R, <i>et al<\/i>. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011; 27: 639-53.","DOI":"10.1002\/dmrr.1239"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Frattola A, Parati G, Gamba P, <i>et al<\/i>. Time and frequency domain estimates of spontaneous baroreflex sensitivity provide early detection of autonomic dysfunction in diabetes mellitus. Diabetologia 1997; 40: 1470-5.","DOI":"10.1007\/s001250050851"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ziegler D, Laude D, Akila F, Elghozi JL. Time- and frequency-domain estimation of early diabetic cardiovascular autonomic neuropathy. Clin Auton Res 2001; 11: 369-76.","DOI":"10.1007\/BF02292769"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. La Rovere MT, Pinna GD, Raczak G. Baroreflex sensitivity: measurement and clinical implications. Ann Noninvasive Electrocardiol 2008; 13: 191-207.","DOI":"10.1111\/j.1542-474X.2008.00219.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Parati G, Di Rienzo M, Mancia G. How to measure baroreflex sensitivity: from the cardiovascular laboratory to daily life. J Hypertens 2000; 18: 7-19.","DOI":"10.1097\/00004872-200018010-00003"},{"key":"11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/01.HYP.28.2.238","volume":"28","year":"1996","unstructured":"11. Watkins LL, Grossman P, Sherwood A. Noninvasive assessment of baroreflex control in borderline hypertension. Comparison with the phenylephrine method. Hypertension 1996; 28: 238-43.","journal-title":"Hypertension","ISSN":"https:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"key":"12","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.hrthm.2012.04.017","volume":"9","year":"2012","unstructured":"12. Barthel P, Bauer A, M\u00fcller A, <i>et al<\/i>. Spontaneous baroreflex sensitivity: prospective validation trial of a novel technique in survivors of acute myocardial infarction. Heart Rhythm 2012; 9: 1288-94.","journal-title":"Heart Rhythm","ISSN":"https:\/\/id.crossref.org\/issn\/1547-5271","issn-type":"print"},{"key":"13","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.HYP.37.3.911","volume":"37","year":"2001","unstructured":"13. Kardos A, Watterich G, de Menezes R, Csan\u00e1dy M, Casadei B, Rudas L. Determinants of spontaneous baroreflex sensitivity in a healthy working population. Hypertension 2001; 37: 911-6.","journal-title":"Hypertension","ISSN":"https:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Laitinen T, Hartikainen J, Vanninen E, Niskanen L, Geelen G, L\u00e4nsimies E. Age and gender dependency of baroreflex sensitivity in healthy subjects. J Appl Physiol (1985) 1998; 84: 576-83.","DOI":"10.1152\/jappl.1998.84.2.576"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lantelme P, Khettab F, Custaud MA, <i>et al<\/i>. Spontaneous baroreflex sensitivity: toward an ideal index of cardiovascular risk in hypertension? J Hypertens 2002; 20: 935-44.","DOI":"10.1097\/00004872-200205000-00029"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bonyhay I, Jokkel G, Kollai M. Relation between baroreflex sensitivity and carotid artery elasticity in healthy humans. Am J Physiol 1996; 271: H1139-44.","DOI":"10.1152\/ajpheart.1996.271.3.H1139"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Chapleau MW, Cunningham JT, Sullivan MJ, Wachtel RE, Abboud FM. Structural versus functional modulation of the arterial baroreflex. Hypertension 1995; 26: 341-7.","DOI":"10.1161\/01.HYP.26.2.341"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Reimann M, Julius U, Haink K, <i>et al<\/i>. LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients. Atherosclerosis 2010; 213: 212-7.","DOI":"10.1016\/j.atherosclerosis.2010.07.019"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Grigoropoulou P, Eleftheriadou I, Zoupas C, <i>et al<\/i>. Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia. Diabetes Vasc Dis Res 2014; 11: 26-33.","DOI":"10.1177\/1479164113508293"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Celovska D, Kruzliak P, Rodrigo L, <i>et al<\/i>. Effect of low dose atorvastatin therapy on baroreflex sensitivity in hypertensives. High Blood Press Cardiovasc Prev 2016; 23: 133-40.","DOI":"10.1007\/s40292-016-0154-3"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Indumathy J, Pal GK, Pal P, <i>et al<\/i>. Decreased baroreflex sensitivity is linked to sympathovagal imbalance, body fat mass and altered cardiometabolic profile in pre-obesity and obesity. Metabolism 2015; 64: 1704-14.","DOI":"10.1016\/j.metabol.2015.09.009"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Beske SD, Alvarez GE, Ballard TP, Davy KP. Reduced cardiovagal baroreflex gain in visceral obesity: implications for the metabolic syndrome. Am J Physiol Heart Circ Physiol 2002; 282: H630-5.","DOI":"10.1152\/ajpheart.00642.2001"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ryan JP, Sheu LK, Verstynen TD, Onyewuenyi IC, Gianaros PJ. Cerebral blood flow links insulin resistance and baroreflex sensitivity. PLOS ONE 2013; 8: e83288.","DOI":"10.1371\/journal.pone.0083288"},{"key":"24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.metabol.2004.11.012","volume":"54","year":"2005","unstructured":"24. Anan F, Takahashi N, Nakagawa M, Ooie T, Saikawa T, Yoshimatsu H. High-sensitivity C-reactive protein is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. Metabolism 2005; 54: 552-8.","journal-title":"Metabolism Clinical and Experimental","ISSN":"https:\/\/id.crossref.org\/issn\/0026-0495","issn-type":"print"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Watkins LL, Surwit RS, Grossman P, Sherwood A. Is there a glycemic threshold for impaired autonomic control? Diabetes Care 2000; 23: 826-30.","DOI":"10.2337\/diacare.23.6.826"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Takahashi N, Anan F, Nakagawa M, <i>et al<\/i>. Hypoadiponectinemia in type 2 diabetes mellitus in men is associated with sympathetic overactivity as evaluated by cardiac 123I-metaiodobenzylguanidine scintigraphy. Metabolism 2007; 56: 919-24.","DOI":"10.1016\/j.metabol.2007.02.005"},{"key":"27","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1161\/01.CIR.97.20.2037","volume":"97","year":"1998","unstructured":"27. Grassi G, Seravalle G, Colombo M, <i>et al<\/i>. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998; 97: 2037-42.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tomiyama H, Matsumoto C, Kimura K, Odaira M, Shiina K, Yamashina A. Pathophysiological contribution of vascular function to baroreflex regulation in hypertension. Circ J 2014; 78: 1414-9.","DOI":"10.1253\/circj.CJ-14-0064"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Pierce GL, Harris SA, Seals DR, Casey DP, Barlow PB, Stauss HM. Estimated aortic stiffness is independently associated with cardiac baroreflex sensitivity in humans: role of ageing and habitual endurance exercise. J Hum Hypertens 2016; 30: 513-20.","DOI":"10.1038\/jhh.2016.3"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Michas F, Manios E, Stamatelopoulos K, <i>et al<\/i>. Baroreceptor reflex sensitivity is associated with arterial stiffness in a population of normotensive and hypertensive patients. Blood Press Monit 2012; 17: 155-9.","DOI":"10.1097\/MBP.0b013e32835681fb"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Matsutani D, Sakamoto M, Iuchi H, <i>et al<\/i>. Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report. Cardiovasc Diabetol 2018; 17: 36.","DOI":"10.1186\/s12933-018-0683-2"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Gianaros PJ, Jennings JR, Olafsson GB, <i>et al<\/i>. Greater intima-media thickness in the carotid bulb is associated with reduced baroreflex sensitivity. Am J Hypertens 2002; 15: 486-91.","DOI":"10.1016\/S0895-7061(02)02923-0"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Parati G, Di Rienzo M, Bertinieri G, <i>et al<\/i>. Evaluation of the baroreceptor-heart rate reflex by 24-hour intra-arterial blood pressure monitoring in humans. Hypertension 1988; 12: 214-22.","DOI":"10.1161\/01.HYP.12.2.214"},{"key":"34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(10)60308-X","volume":"375","year":"2010","unstructured":"34. Rothwell PM, Howard SC, Dolan E, <i>et al<\/i>. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Ruan Y, Wei W, Yan J, <i>et al<\/i>. Time rate of blood pressure variation is associated with endothelial function in patients with metabolic syndrome. Int Heart J 2016; 57: 226-33.","DOI":"10.1536\/ihj.15-322"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Skrapari I, Tentolouris N, Perrea D, Bakoyiannis C, Papazafiropoulou A, Katsilambros N. Baroreflex sensitivity in obesity: relationship with cardiac autonomic nervous system activity. Obesity (Silver Spring) 2007; 15: 1685-93.","DOI":"10.1038\/oby.2007.201"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Takahashi N, Nakagawa M, Saikawa T, <i>et al<\/i>. Effect of essential hypertension on cardiac autonomic function in type 2 diabetic patients. J Am Coll Cardiol 2001; 38: 232-7.","DOI":"10.1016\/S0735-1097(01)01363-8"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Zhou TL, Kroon AA, Reesink KD, <i>et al<\/i>. Blood pressure variability in individuals with and without (pre) diabetes: the Maastricht Study. J Hypertens 2017; 36: 259-67.","DOI":"10.1097\/HJH.0000000000001543"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. de Leeuw PW, Bisognano JD, Bakris GL, <i>et al<\/i>. Sustained reduction of blood pressure with baroreceptor activation therapy: results of the 6-year open follow-up. Hypertension 2017; 69: 836-43.","DOI":"10.1161\/HYPERTENSIONAHA.117.09086"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Spiering W, Williams B, Van der Heyden J, <i>et al<\/i>. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet 2017; 390: 2655-61.","DOI":"10.1016\/S0140-6736(17)32337-1"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Floyd CN, Adeel MY, Wolff CB, <i>et al<\/i>. First-in-man treatment of severe blood pressure variability with baroreflex activation therapy. Int J Cardiol 2016; 220: 577-9.","DOI":"10.1016\/j.ijcard.2016.06.308"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Dell&apos;Oro R, Gronda E, Seravalle G, <i>et al<\/i>. Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: final 43-month study report. J Hypertens 2017; 35: 2532-6.","DOI":"10.1097\/HJH.0000000000001498"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Bisognano JD, Kaufman CL, Bach DS, Lovett EG, de Leeuw P. DEBuT-HT and Rheos Feasibility Trial Investigators. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol 2011; 57: 1787-8.","DOI":"10.1016\/j.jacc.2010.11.048"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Abraham WT, Zile MR, Weaver FA, <i>et al<\/i>. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail 2015; 3: 487-96.","DOI":"10.1016\/j.jchf.2015.02.006"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Eguchi K, Tomizawa H, Ishikawa J, <i>et al<\/i>. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure. J Cardiovasc Pharmacol 2007; 49: 394-400.","DOI":"10.1097\/FJC.0b013e31804d1cf1"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Kishi T, Hirooka Y, Konno S, Sunagawa K. Cilnidipine inhibits the sympathetic nerve activity and improves baroreflex sensitivity in patients with hypertension. Clin Exp Hypertens 2009; 31: 241-9.","DOI":"10.1080\/10641960902822492"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Haberth\u00fcr C, Sch\u00e4chinger H, Langewitz W, Ritz R. Effect of beta blockade with and without sympathomimetic activity (ISA) on sympathovagal balance and baroreflex sensitivity. Clin Physiol 1999; 19: 143-52.","DOI":"10.1046\/j.1365-2281.1999.00162.x"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Chern CM, Hsu HY, Hu HH, Chen YY, Hsu LC, Chao AC. Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension. J Cardiovasc Pharmacol 2006; 47: 169-74.","DOI":"10.1097\/01.fjc.0000199225.17928.f5"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Marakas SA, Kyriakidis MK, Vourlioti AN, Petropoulakis PN, Toutouzas PK. Acute effect of captopril administration on baroreflex sensitivity in patients with acute myocardial infarction. Eur Heart J 1995; 16: 914-21.","DOI":"10.1093\/oxfordjournals.eurheartj.a061025"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Wang JG, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials. J Am Soc Hypertens 2014; 8: 340-9.","DOI":"10.1016\/j.jash.2014.02.004"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Kollias A, Stergiou GS, Kyriakoulis KG, Bilo G, Parati G. Treating visit-to-visit blood pressure variability to improve prognosis: is amlodipine the drug of choice? Hypertension 2017; 70: 862-6.","DOI":"10.1161\/HYPERTENSIONAHA.117.10087"},{"key":"52","doi-asserted-by":"publisher","unstructured":"52. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553-79.","DOI":"10.2337\/diacare.26.5.1553"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Gerritsen J, Dekker JM, TenVoorde BJ, <i>et al<\/i>. Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study. Diabetologia 2000; 43: 561-70.","DOI":"10.1007\/s001250051344"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Wu JS, Lu FH, Yang YC, <i>et al<\/i>. Impaired baroreflex sensitivity in subjects with impaired glucose tolerance, but not isolated impaired fasting glucose. Acta Diabetol 2014; 51: 535-41.","DOI":"10.1007\/s00592-013-0548-9"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Cardoso CRL, Leite NC, Moram CBM, Salles GF. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc Diabetol 2018; 17: 33.","DOI":"10.1186\/s12933-018-0677-0"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Gorst C, Kwok CS, Aslam S, <i>et al<\/i>. Long-term glycemic variability and risk of adverse outcomes: A systematic review and meta-analysis. Diabetes Care 2015; 38: 2354-69.","DOI":"10.2337\/dc15-1188"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Hirakawa Y, Arima H, Zoungas S, <i>et al<\/i>. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care 2014; 37: 2359-65.","DOI":"10.2337\/dc14-0199"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Muggeo M, Zoppini G, Bonora E, <i>et al<\/i>. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000; 23: 45-50.","DOI":"10.2337\/diacare.23.1.45"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Matsutani D, Sakamoto M, Minato S, <i>et al<\/i>. Visit-to-visit HbA1c variability is inversely related to baroreflex sensitivity independently of HbA1c value in type 2 diabetes. Cardiovasc Diabetol 2018; 17: 100.","DOI":"10.1186\/s12933-018-0743-7"},{"key":"60","doi-asserted-by":"publisher","unstructured":"60. Ceriello A, Esposito K, Piconi L, <i>et al<\/i>. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57: 1349-54.","DOI":"10.2337\/db08-0063"},{"key":"61","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.295.14.1681","volume":"295","year":"2006","unstructured":"61. Monnier L, Mas E, Ginet C, <i>et al<\/i>. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681-7.","journal-title":"JAMA The Journal of the American Medical Association","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Costantino S, Paneni F, Battista R, <i>et al<\/i>. Impact of glycemic variability on chromatin remodeling, oxidative stress, and endothelial dysfunction in Type 2 diabetic patients with target HbA1c levels. Diabetes 2017; 66: 2472-82.","DOI":"10.2337\/db17-0294"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Ceriello A, Esposito K, Piconi L, <i>et al<\/i>. Glucose &quot;peak&quot; and glucose &quot;spike&quot;: impact on endothelial function and oxidative stress. Diabetes Res Clin Pract 2008; 82: 262-7.","DOI":"10.1016\/j.diabres.2008.07.015"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Wei F, Sun X, Zhao Y, Zhang H, Diao Y, Liu Z. Excessive visit-to-visit glycemic variability independently deteriorates the progression of endothelial and renal dysfunction in patients with type 2 diabetes mellitus. BMC Nephrol 2016; 17: 67.","DOI":"10.1186\/s12882-016-0300-0"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Ulleryd MA, Prahl U, B\u00f6rsbo J, <i>et al<\/i>. The association between autonomic dysfunction, inflammation and atherosclerosis in men under investigation for carotid plaques. PLOS ONE 2017; 12: e0174974.","DOI":"10.1371\/journal.pone.0174974"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Ruiz J, Monbaron D, Parati G, <i>et al<\/i>. Diabetic neuropathy is a more important determinant of baroreflex sensitivity than carotid elasticity in type 2 diabetes. Hypertension 2005; 46: 162-7.","DOI":"10.1161\/01.HYP.0000169053.14440.7d"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Yokoe H, Yuasa F, Yuyama R, <i>et al<\/i>. Effect of pioglitazone on arterial baroreflex sensitivity and sympathetic nerve activity in patients with acute myocardial infarction and type 2 diabetes mellitus. J Cardiovasc Pharmacol 2012; 59: 563-9.","DOI":"10.1097\/FJC.0b013e31824f91a7"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Zhao D, McCully BH, Brooks VL. Rosiglitazone improves insulin sensitivity and baroreflex gain in rats with diet-induced obesity. J Pharmacol Exp Ther 2012; 343: 206-13.","DOI":"10.1124\/jpet.112.194738"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Guo JM, Zhang L, Niu XC, <i>et al<\/i>. Involvement of arterial baroreflex and nicotinic acetylcholine receptor \u03b1 7 subunit pathway in the protection of metformin against stroke in stroke-prone spontaneously hypertensive rats. Eur J Pharmacol 2017; 798: 1-8.","DOI":"10.1016\/j.ejphar.2017.01.035"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Neal B, Perkovic V, Mahaffey KW, <i>et al<\/i>. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med 2017; 377: 644-57.","DOI":"10.1056\/NEJMoa1611925"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Zinman B, Wanner C, Lachin JM, <i>et al<\/i>. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med 2015; 373: 2117-28.","DOI":"10.1056\/NEJMoa1504720"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Naito R, Miyauchi K. Coronary artery disease and type 2 diabetes mellitus. Int Heart J 2017; 58: 475-80.","DOI":"10.1536\/ihj.17-191"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Wenzel RR, Bruck H, Noll G, Sch\u00e4fers RF, Daul AE, Philipp T. Antihypertensive drugs and the sympathetic nervous system. J Cardiovasc Pharmacol 2000; 35 (7 Suppl 4) : S43-52.","DOI":"10.1097\/00005344-200000004-00006"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Yoshikawa T, Kishi T, Shinohara K, <i>et al<\/i>. Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. Hypertens Res 2017; 40: 646-51.","DOI":"10.1038\/hr.2017.14"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Iuchi H, Sakamoto M, Matsutani D, <i>et al<\/i>. Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis. Sci Rep 2017; 7: 11906.","DOI":"10.1038\/s41598-017-12106-y"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol 2018; 17: 73.","DOI":"10.1186\/s12933-018-0717-9"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Reimann M, R\u00fcdiger H, Weiss N, Ziemssen T. Acute hyperlipidemia but not hyperhomocysteinemia impairs reflex regulation of the cardiovascular system. Atheroscler Suppl 2015; 18: 8-15.","DOI":"10.1016\/j.atherosclerosissup.2015.02.004"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Kaur M, Chandran DS, Jaryal AK, Bhowmik D, Agarwal SK, Deepak KK. Baroreflex dysfunction in chronic kidney disease. World J Nephrol 2016; 5: 53-65.","DOI":"10.5527\/wjn.v5.i1.53"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/60\/2\/60_18-455\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T01:57:00Z","timestamp":1574042220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/60\/2\/60_18-455\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,30]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.18-455","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,30]]}}}